JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit forecasts ...

Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year, or ...

Shares of Teva Pharmaceutical (NYSE:TEVA) gained in the premarket trading on Wednesday after the generic drugmaker reported better-than-expected Q3 2024 financials and raised its full-year outlook ...

With Donald Trump now poised to become U.S. president for the second time in January, biotech and pharmaceutical leaders are preparing for the shift to an administration with a complicated history ...

The United States Department of Justice (DOJ) recently announced that Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. will pay $450 million to resolve allegations of violating the ...

On October 31, 2024, the European Commission issued a fine of €462.6 million to Teva Pharmaceuticals, citing abuse of its market dominance by delaying competition for Copaxone, a leading multiple ...

Teva Pharmaceutical Industries Ltd. (TEVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most ...

York Regional Police are appealing to the public for information on a serious motorcycle crash in Whitchurch-Stouffville. The single-vehicle collision happened Thursday around 9 p.m. in the area ...

To do that, Teva conducted a "disparagement campaign" against Synthon, the only other company with an authorised drug in Europe containing glatiramer acetate, the Commission said in a statement.

Copyright 2024 The Associated Press. All Rights Reserved. FILE - Israeli flag flies outside Teva Pharmaceutical facility building in Neot Hovav, Israel, on Dec. 14 ...